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Background: When there are structural relationships between outcomes reported
in different trials, separate analyses of each outcome do not provide a single coher-
ent analysis, which is required for decision-making. For example, trials of intra-
partum anti-bacterial prophylaxis (IAP) to prevent early onset group B
streptococcal (EOGBS) disease can report three treatment effects: the effect on bac-
terial colonisation of the newborn, the effect on EOGBS, and the effect on EOGBS
conditional on newborn colonisation. These outcomes are conditionally related, or
nested, in a multi-state model.
This paper shows how to exploit these structural relationships, providing a single
coherent synthesis of all the available data, while checking to ensure that different
sources of evidence are consistent.
Results: Overall, the use of IAP reduces the risk of EOGBS (RR: 0.03; 95% Credi-
ble Interval (CrI): 0.002–0.13). Most of the treatment effect is due to the prevention
of colonisation in newborns of colonised mothers (RR: 0.08, 95% CrI: 0.04–0.14).
Node-splitting demonstrated that the treatment effect calculated using only direct evi-
dence was consistent with that predicted from the remaining evidence (p = 0.15).
The findings accorded with previously published separate meta-analyses of the dif-
ferent outcomes, once these are re-analysed correctly accounting for zero cells.
Conclusion: Multiple outcomes should be synthesised together where possible,
taking account of their structural relationships. This generates an internally coher-
ent analysis, suitable for decision making, in which estimates of each of the treat-
ment effects are based on all available evidence (direct and indirect). Separate
meta-analyses of each outcome have none of these properties.
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Bayesian, Early onset group B streptococcus, Intrapartum antibiotic prophylaxis, Meta-analysis,
Multi-outcome synthesis, Multi-state models
1 | INTRODUCTION
Health technology assessments are carried out to evaluate
the efficacy of medical interventions, and inform a decision
of whether to use them for a particular group of
patients. Usually these assessments rely on a systematic
review of the literature, followed by a meta-analysis. It is
considered good practice to define the main review outcome
a priori with other outcomes of interest classified as
secondary and each outcome analysed separately.1-3
Received: 11 February 2019 Revised: 20 August 2019 Accepted: 16 September 2019
DOI: 10.1002/jrsm.1380
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2019 The Authors. Research Synthesis Methods published by John Wiley & Sons Ltd
Res Syn Meth. 2019;1–11. wileyonlinelibrary.com/journal/jrsm 1
However, often outcomes are known to be related. A joint
synthesis of all related outcomes, where their relationship
(including any correlations) is taken into account, is prefera-
ble as it will use all the relevant evidence in a single coher-
ent analysis.
One approach to multiple outcome synthesis has been
multivariate normal random effects (MVNRE) models tak-
ing account of correlations between outcomes, both within
and between studies.4,5 Alternatively, multi-parameter evi-
dence synthesis (MPES) uses different data sources to
inform parameters which are related in a mathematical
model,6-8 thus capturing structural and logical relationships
between outcomes, and generating outputs that have a natu-
ral clinical interpretation.
In this paper, we present a particular type of multiple out-
come data where outcomes are nested, that is, some events
can only occur in individuals who already had a previous
(related) event. In other words, there is a logical chain of
events which occur in a known sequence, with each outcome
conditional on the occurrence of the previous outcome. We
will present an illustrative example where evidence on such
conditional outcomes is available, forming a multi-state
model. We will show how to incorporate all the outcomes
into a single meta-analysis and how to check for potential
conflict between evidence sources. Finally, we highlight the
benefits of our approach compared to previous meta-analysis
models.
2 | ILLUSTRATIVE EXAMPLE:
EARLY ONSET GROUP B
STREPTOCOCCAL DISEASE
Our study looks at trials of intrapartum antibiotic prophy-
laxis (IAP) to prevent early onset group B streptococcal
(EOGBS) disease in newborns. Newborns can probably only
develop EOGBS if they have been colonised by the bacteria,
which in turn is only possible if the mother was a group B
streptococcus (GBS) carrier during labour9,10 (Figure 1).
Maternal colonisation with GBS is relatively common,
averaging 18% but varying from 11%- 35% in different
countries.11 EOGBS occurs in 0.43 per 1000 births world-
wide,12 with wide variation between regions. EOGBS is
associated with high rates of meningitis and neonatal
encephalopathy, with a 12.1% case fatality.12 At least 60
countries have adopted preventative strategies, ranging from
IAP for women identified at high risk to universal screening
for maternal carriage and IAP in those screened positive.13
The efficacy of IAP is widely recognised based both on
randomised control trials and on a range of observational
data.14 However, the best preventative strategy remains
controversial.15-17
Several trials have been conducted on women colonised
with GBS; some have reported neonatal colonisation as the
outcome, some neonatal EOGBS disease, and others both.
We number these outcomes (or states) maternal colonisation
(1), newborn colonisation (2), and EOGBS (3).
FIGURE 1 Multi-state model structure for the EOGBS example
HIGHLIGHTS
What is already known?
Most previous estimates for the effectiveness of
Intrapartum antibiotic prophylaxis for early onset
group B streptococcal (EOGBS) disease were
biased due to inappropriate methods being applied
to meta-analyse studies with strong treatment effects
and a large number of zero cells.
What is new?
Synthesis using multi-state models delivers a single
coherent analysis of multiple evidence sources using
conditional relationships. The relative treatment
effects estimated are more precise than when sepa-
rate analyses were conducted.
Potential impact for Review Synthesis
Methods readers outside the authors'
field
Wherever possible, multiple outcomes should be
synthesised together in a single coherent analysis,
capturing the clinical and structural relationships
between them. A single set of coherent estimates
improves the robustness and allows a better
understanding of the effectiveness of the interven-
tion, facilitating decision-making.
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A change in state is referred to as a transition.18-20 The
transition between states are labelled as 1 ! 2, 2 ! 3 and
1 ! 3. Table 1 reports all the aggregate data available from
eight studies21-28 that compare the effectiveness of IAP
administered to mothers intravenously to a placebo or con-
trol. Multiple births were rare in the data, and therefore the
lack of independence between twins in the data was
ignored.29 Studies 1–3, 6 and 8 report both infant colonisa-
tion and EOGBS outcomes, and thus provide evidence on all
three transitions. Studies 4 and 5 report only infant colonisa-
tion and thus provide evidence on the 1 ! 2 transition only.
Study 7 only provides evidence on the proportion of patients
making both a 1 ! 2 and 2 ! 3 transition. Standard meta-
analytic methods have been applied to both the 1 ! 230 and
1 ! 39,30-32 effects. The difficulty with having separate,
unrelated meta-analyses is that these are not independent as
some of the trials are involved in both and because the
1 ! 2 effect is part of the 1 ! 3 effect. Also, it is unclear
how one can draw an overall conclusion from the two sets
of estimates produced.
In addition, relevant evidence from two studies (420 and
521 in Table 1) would be excluded from a meta-analysis
where the outcome of interest was EOGBS given maternal
colonisation. The large number of zero counts in the IAP
treatment arm (because the treatment is very effective), adds
further complexity to the analysis.
3 | METHODS
3.1 | Data and likelihoods
Let rx ! y,ik denote the number of individuals with event of
type y given previous state x in arm k of trial i where x = 1,
2 represents maternal colonisation or neonatal colonisation
and y = 2, 3 represents neonatal colonisation and EOGBS,
respectively (Figure 1, Table 1). The likelihoods conditional
on a previous outcome are binomial:
rx!y, ik e Binomial πx!y, ik,nx, ik  ð1Þ
where πx ! y,ik represent the conditional probabilities of
achieving outcome y = 2, 3 for individuals in state
x = 1, 2, that is the probability of transitioning from
1 ! 2, 2 ! 3 or 1 ! 3; and nx,ik represent the number
of individuals in state x, that is n1,ik, the number of
women colonised with GBS and n2,ik the number of
colonised newborns in arm k of trial i.
The likelihoods in Equation (1) take into account the
information available in each study.
For example, studies 1–521-25 and 828 provide data on
neonatal colonisation (2) given maternal colonisation (1).
Therefore, we can estimate the probability of transitioning
from 1 ! 2 in each of these studies by specifying a likeli-
hood for r1 ! 2,ik using the total number of colonised women
as the denominator.
Study 727 provides information only on EOGBS (3)
given maternal colonisation (1) thus we can estimate the
probability of transitioning from 1! 3 in this study by spec-
ifying a likelihood for r1 ! 3,ik using the total number of
colonised women as the denominator.
Additionally, studies 1–321-23 and 828 also provide data
on EOGBS (3). Rather than use this data to estimate the
1 ! 3 probabilities, which would involve “double counting”
as it is not independent of the 1 ! 2 data, we can instead
estimate the probability of transitioning from 2 ! 3 by spec-
ifying a likelihood for r2 ! 3,ik conditioning on the total
TABLE 1 Study details for intrapartum antibiotic prophylaxis for the prevention of EOGBS in newborns. The number of individuals
experiencing an event x (where 1 = maternal colonisation, 2 = neonatal colonisation and 3 = EOGBS) in a study i for the placebo (k = 1) and IAP
(k = 2) arms are denoted by rx,ik
Maternal colonisation (1) Neonatal colonisation (2) EOGBS (3)
Placebo IAP Placebo IAP Placebo IAP
r1, i1
*
r1, i2
*
r2, i1 r2, i2 r3, i1 r3, i2
1. Boyer (1982) 21 82 69 46 2 4 0
2. Boyer (1983) 22 37 43 13 1 1 0
3. Matorras (1991) 23 56 54 24 2 3 0
4. Easmon (1983) 24 49 38 17 0
5. Yow (1979) 25 24 34 14 0
6. Morales (1986) 26 128 135 59 0 2 0
7. Tuppurainen (1989) 27 111 88 4 1
8. Boyer (1986) 28 79 85 40 8 5 0
*These are the total number of individuals that were randomised.
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number of colonised newborns n2,ik as the denominator.
These studies contribute indirect evidence on the probability
of transitioning from 1 ! 3 (see Section 3.2).
Study 626 was used to inform the overall treatment
effect (1 ! 3) instead of using the results to inform tran-
sitions 1 ! 2 and 2 ! 3 separately as it effectively pro-
vides no information on the latter transition, since no
newborns in the IAP arm were colonised (leading to a
denominator of 0 when describing the 2 ! 3 transition).
Therefore, six studies provide evidence to the 1 ! 2
transition, four to the 2 ! 3 transition, and 2 to the
1 ! 3 transition for the multiple-outcome meta-analysis
model for EOGBS.
To combine all data in a single, coherent analysis, we
need to express the relationship between the relative
treatment effects on the 1 ! 2, 2 ! 3, and 1 ! 3
transitions.
3.2 | Relationships between states
A relationship can be established between the Relative Risks
(RRs) estimated from the three sources of evidence. The RR
for the 1 ! 2 transition is defined as:
RR 1! 2ð Þ=
Pr 1! 2jTð Þ
Pr 1! 2jCð Þ
ð2Þ
where Pr(1 ! 2| T) and Pr(1 ! 2| C) are the probabilities
of neonatal colonisation conditional on maternal colonisa-
tion under IAP and control, respectively.
Similarly, the RR for the 2 ! 3 transition is defined as:
RR 2! 3ð Þ=
Pr 2! 3jTð Þ
Pr 2! 3jCð Þ
ð3Þ
Assuming the transitions 1! 2 and 2! 3 are conditionally
independent, it follows that:
RR 1! 2ð ÞRR 2! 3ð Þ =
Pr 1! 2jTð Þ
Pr 1! 2jCð Þ

Pr 2! 3jTð Þ
Pr 2! 3jCð Þ
=
Pr 1! 3jTð Þ
Pr 1! 3jCð Þ
= RR 1! 3ð Þ
ð4Þ
We define the RR on the 1 ! 2 and 2 ! 3 transitions as the
basic parameters33,34 to be estimated and will impose the
constraint RR(1 ! 3) = RR(1 ! 2)  RR(2 ! 3) (Equation
(4)). Note that no such relationship exists if the treatment
effect is defined in terms of the Risk Difference or Odds
Ratio.
3.3 | Meta-analysis models
3.3.1 | Multi-state model
A Bayesian multi-state model (referred to as the base-case
model) estimates the log relative risks (LRRs) whilst ensur-
ing that estimated probabilities remain between zero and
one,35 and incorporating Equation (4).
Using the likelihood defined in Equation (1), the LRRs
for the control and treatment arms for any transition x ! y,
are modelled as:
log πx!y, i1
 
= μx!y, i
log πx!y, i2
 
= μx!y, i + min δx!y, i, −μx!y, i
  ð5Þ
For a trial i, μx ! y,i is the log of the probability of the tran-
sition in the control arm of trial i, which is given a non-
informative prior distribution, Uniform (0,1) , and consid-
ered a nuisance parameter.35 At the same time the LRR,
δx ! y,i, is constrained to ensure probabilities remain
between zero and 1.35,36
Then, in an FE model δx ! y,i = dx ! y, while for an RE
model, we write:
δx!y, i e Normal dx!yσ2x!y
 
ð6Þ
where dx ! y is the mean treatment effect and σ
2
x!y the
between-study heterogeneity variance. The RE model was
used to model the LRR of neonatal colonisation on maternal
colonisation (transition 1 ! 2) as:
δ1!2, i e Normal d1!2σ21!2 
d1!2 e Normal 0, 1000ð Þ
σ1!2 e Half −Normal 0, 0:322 
ð7Þ
The half-normal prior distribution for the between-trial
standard deviation generates only positive values, and its
variance is chosen so that the 95% Credible Interval (CrI)
for the effects of trials lies within a factor of 2 from the
median.36
The LRR of EOGBS conditional on neonatal colonisa-
tion (transition 2 ! 3) is modelled using a FE model due to
data sparseness:
δ2!3, i = d2!3 e Normal 0, 10ð Þ ð8Þ
The relationship in Equation (4), on the log-scale, is used to
describe the overall treatment effect (transition 1 ! 3), as
the sum of a random effect for the 1 ! 2 transition and a
fixed effect for 2 ! 3:
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δ1!3, i e Normal d1!3σ21!3 
d1!3 = d1!2 + d2!3
: ð9Þ
This captures the assumption that the relative treatment
effect for 2 ! 3, d2 ! 3, has a fixed effect, forcing the vari-
ance of 1 ! 3 to be the same as the variance of 1 ! 2.
3.3.2 | Sensitivity analyses
Modelling assumptions regarding the way trials 6 and 7
were incorporated in the base-case model were investigated
in sensitivity analyses. In a second multi-state model, Sensi-
tivity Analysis (SA) 1, the overall treatment effect is mod-
elled using a FE model where δ1 ! 3,i = d1 ! 3 with d1 ! 3
defined in Equation (9). A third model, SA 2, assumed that
all the effect of IAP in EOGBS is achieved through
preventing neonatal colonisation: thus we set d2 ! 3 = 0,
resulting in d1 ! 3 = d1 ! 2.
We also examined more informative and less informative
prior distributions for the between-trial standard deviation
σ1 ! 2. These were Half-Normal (0, 0.19
2) and Half-Normal
(0, 0.502), which imply that 95% of the trial effects are
within a factor of 1.5 and 3.0 from the median, respectively.
A t-distribution prior with a mean of zero and two
degrees of freedom was used to investigate the sensitivity of
the prior for d (Supplementary Figures S2 and S3).
3.3.3 | Standard meta-analysis models
Standard Bayesian meta-analysis models were also applied,
using the same priors as the multi-state models; an RE
model for the 1 ! 2 transition and both FE and RE models
for the 2 ! 3 and 1 ! 3 transitions using a binomial likeli-
hood,37,38 in each case using all the data available on each
transition. These analyses are not independent but are pres-
ented for comparison.
3.4 | Model estimation
Models were estimated by Markov Chain Monte Carlo
(MCMC) methods in WinBUGS 1.4.3.39 The multi-state
structures are implemented by adapting the code given in
Dias, Ades, Welton, Jansen, Sutton 36 for ‘chains of evi-
dence’ structures, included in the Supplementary Files (Sup-
plementary File S4).
Convergence was assessed as having occurred within
15,000 iterations using the Brooks-Gelman-Rubin (BGR)
diagnostic 40 and trace plots. We discarded the first 200,000
samples (burn in), and based inference on 100, 000 samples
from each of four chains.
3.4.1 | Model fit
The fit of the models is checked using the total residual
deviance and by inspecting deviance plots.41 The residual
deviance is the posterior mean of the deviance of the
model removing the deviance for a saturated model.42 For
models that fit the data well, the residual deviance is
expected to be close to the number of unconstrained data
points. Model comparison can be conducted by using
DIC to compare the base-case model, SA 1 and SA 2.
The DIC measures the goodness of fit penalising for the
effective number of parameters.41 Lower values of DIC
are preferred with differences greater than 3 to 5 points,
being considered important.
3.4.2 | Checking conflict
Node-splitting43 was used to check for conflict between the
“direct” evidence on the RR for the 1 ! 3 transition from
studies 6 and 7, and the “indirect” evidence from the rest of
the data.
Therefore, we define dDir1!3 as:
dDir1!3 e Normal 0,1000ð Þ ð10Þ
while the “indirect” estimate is calculated as
dInd1!3 = d1!2 + d2!3 and compared to d
Dir
1!3 using a Bayesian
“p-value” 43,44:
pB =Pr d
Dir
1!3 ≥ d
Ind
1!3
 
ð11Þ
In an MCMC framework, this p-value is calculated as the
proportion of iterations where dDir1!3 ≥ d
Ind
1!3. If pB is less than
0.5, the two-sided p-value is 2 × pB, otherwise it is 2×
(1-pB).
43
The fit of the node-split model is also compared to the fit
of the base-case model using the residual deviance and
DIC.41 The changes in between-study heterogeneity can also
be used to compare the heterogeneity of the base-case and
node-split models.45
4 | RESULTS
4.1 | Multi-state model
The overall treatment effect using all available relevant evi-
dence shows that administering IAP to mothers prevents
EOGBS in newborns (RR: 0.03, 95% CrI: 0.002, 0.13). The
results from the base-case model (Table 2 and Figure 2) indi-
cate that IAP primarily prevents EOGBS disease by
preventing colonised mothers from infecting their newborns,
i.e. during transition 1 ! 2 (RR: 0.08, 95% CrI: 0.04, 0.14).
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There is insufficient evidence to determine whether IAP has
an additional treatment effect on preventing EOGBS in
colonised newborns, i.e. transition 2 ! 3 (RR: 0.33, 95%
CrI: 0.03, 1.54). The residual deviance for the base-case
model is 25.5 compared to 24 data points included in the
analysis, indicating a good fit.
TABLE 2 Median relative risks (RR) with 95% Credible Intervals (CrI), between-trials standard deviance (σ) for the 1 ! 2 transition, and
model fit statistics for the base-case model and sensitivity analysis. All 8 studies in Table 1 were included in each model
Model
Residual
deviance† DIC
σ1 ! 2
(95% CrI)
RR1 ! 2
(95% CrI)
RR2 ! 3
(95% CrI)
RR1 ! 3
(95% CrI)
Base-case
Base-case δ1 ! 3,i = δ1 ! 2,new+d2 ! 3 25.5 96.3 0.278
(0.011, 0.765)
0.081
(0.039, 0.143)
0.331
(0.026, 1.538)
0.026
(0.002, 0.130)
Sensitivity analyses: Modelling assumptions
SA 1 δ1!3, i ¼ d1!3
¼ d1!2 + d2!3
25.7 96.5 0.273
(0.015, 0.750)
0.081
(0.039, 0.144)
0.341
(0.025, 1.586)
0.027
(0.002, 0.137)
SA 2 d2 ! 3 = 0 25.3 95.3 0.279
(0.017, 0.757)
0.079
(0.038, 0.139)
1.000
(fixed)
0.079
(0.038, 0.139)
Sensitivity analyses: Assumptions about between-trials variation on the 1! 2 relative treatment effect
SA 3 σ1 ! 2 = 0 (FE) 27.5 97.2 -- 0.087
(0.049, 0.142)
0.333
(0.026, 1.551)
0.029
(0.002, 0.140)
SA 4 σ1 ! 2~Half − Normal
(0,0.192)
26.5 96.7 0.152
(0.009, 0.463)
0.085
(0.045, 0.141)
0.324
(0.023, 1.550)
0.027
(0.002, 0.137)
SA 5 σ1 ! 2~Half − Normal
(0,0.502)
24.5 96.0 0.434
(0.029, 1.128)
0.077
(0.031, 0.147)
0.331
(0.025, 1.551)
0.025
(0.002, 0.129)
Sensitivity analysis: Assumptions about treatment effects
SA 6 d1!2 e Student df ¼ 2ð Þ
d2!3 e Student df ¼ 2ð Þ
25.5 96.3 0.277
(0.014, 0.764)
0.081
(0.039, 0.143)
0.341
(0.025, 1.571)
0.027
(0.002, 0.137)
† Compare to 24 datapoints
FIGURE 2 Comparative forest plots
representing the relative risks and 95% Credible
Intervals (CrIs) for the treatment effects of IAP on
EOGBS for the (a) base-case model (BC), (b)
Sensitivity Analysis 1 (SA 1), (c) Sensitivity
Analysis 2 (SA 2), and (d) standard random
effects model (RE MA)
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4.2 | Sensitivity analyses
Models SA 1 and SA 2 appear to fit the data as well as the
base-case model (Table 2). The RRs estimated for SA 1
were consistent with those of the base-case model (Table 2).
As the RR for the 2 ! 3 transition for SA 2 is set to 0,
RR1 ! 3 = RR1 ! 2 (Table 2) but the estimated RR1 ! 2 is
still consistent with that estimated in the base-case model.
No meaningful changes are observed in the estimated
between-study heterogeneity in models SA 1 or 2 compared
to the base-case model.
The treatment effect of IAP also remained consistent
when the prior distributions for the heterogeneity of the
1 ! 2 transition were varied although the estimates of het-
erogeneity changed (Table 2). The effect of the different
prior distributions on the posterior distributions is shown in
the Supplementary Material, S1.
4.3 | Standard Meta-analysis models
Table 3 shows the results for the standard meta-analysis
models. The differences between the FE and RE models are
negligible for transitions 2 ! 3 and 1 ! 3. RR1 ! 3 for the
standard meta-analysis models is consistent with the RR esti-
mated for all multi-state models except SA 2. The RR esti-
mated for the 1 ! 2 transition using standard meta-analysis
is lower than the RR obtained from the multi-state models.
The RR for the 2 ! 3 transition is zero. This is due to no
cases of EOGBS being observed in the IAP arm in any of
the included trials.
4.4 | Checking conflict
There was no evidence of conflict between the overall treat-
ment effects on EOGBS (Direct: 0.01 (4 × 10−5, 0.08), Indi-
rect: 0.10 (0.004, 0.70), p-value: 0.15). The node-splitting
model also appears to fit the data adequately. The residual
deviance for 24 datapoints is 23.3 and the DIC is 94.7. The
between-study SD for transition 1 ! 2 is 0.29 (0.01, 0.78),
similar to σ1 ! 2 obtained in the base-case model (Table 2).
The RRs observed for the node-splitting models yielded con-
clusions for the overall treatment effect consistent with those
from the multi-state and standard meta-analysis models.
5 | DISCUSSION
We have proposed a model which delivers a single coherent
analysis of three nested outcomes and checked the core
assumptions to the extent possible. Joint modelling of all the
outcomes ensures that all relevant trials provide information
on all relative effects of interest, directly or indirectly. The
results confirm that the effect of IAP on EOGBS is very
strong, eliminating approximately 97.4% (95% CrI: 87.0% -
99.8%) of EOGBS, and suggesting that most of this effect
occurs by preventing newborn colonisation. Previous
authors9,31 also suggest that IAP reduces GBS colonisation
in mothers, in turn reducing the transmission to newborns
through reduced exposure to GBS during labour.
We have found IAP to be more effective than most previ-
ous researchers, but this appears to be mainly because biased
estimation methods have been used (Table 4). Smaill
(2000)30 uses the Peto ‘one-step’ method51 which is biased
for unbalanced data or large treatment effects52. Benitz
(1999)31 and Ohlsson (2014)9 used Mantel–Haenszel (M-H)
but added a continuity correction factor of 0.5 to cells with
zero counts which is not only unnecessary but also incor-
rect.53 The use of continuity correction with sparse data
results in bias and poor coverage.54,55 The size of these
biases, in this case, can be seen by comparing published esti-
mates to the estimates based on Bayesian Fixed Effect and
M-H method without continuity correction (Table 4). Our
findings with multi-state models concur with previous work
when appropriate methods were used.
The traditional systematic review and meta-analysis
approach forces investigators to choose a “primary” outcome
TABLE 3 Relative risks and model fit statistics for standard fixed and random effects meta-analysis models. Between-study SD for the random
effects models are also included. Some studies were included in more than one meta-analysis
Number of
studies
Number of
Datapoints
Fixed effects model Random effects model
Estimate
Residual
deviance Estimate
Between-study
SD
Residual
deviance
RR1 ! 2 7 14 0.059
(0.032, 0.098)
18.3 0.055
(0.029, 0.099)
0.216
(0.010, 0.719)
14.8
RR2 ! 3
† 4 8 0.000
(0.000, 4.898)
-- --- --- ---
RR1 ! 3 6 12 0.030
(0.001, 0.171)
10.7 0.029
(0.001, 0.169)
0.216
(0.010, 0.718)
10.7
† The data for the 2 ! 3 transition did not allow the use of Bayesian models or the M-H method to estimate RRs. The RR for the 2 ! 3 transition was generated using
the exact method46 in the exactmeta47 package in R 3.4.1.
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TABLE 4 Results obtained for previous studies
Univariate estimates
Transition Studies included Method used in study
Pooled estimate
reported in study
Mantel–Haenszel (M-H) OR
(no continuity correction)
Bayesian fixed
effect OR
Smaill (2000)30 1 ! 2 Boyer (1986)28 Peto OR 0.10 (0.07, 0.14) 0.037 (0.018, 0.074) 0.037 (0.017, 0.069)
Easmon (1983)24
Matorras (1991)23
Morales (1986)26
Smaill (2000)30 1 ! 3 Boyer (1986)28 Peto OR 0.17 (0.07, 0.39) 0.051 (0.007, 0.375) 0.034 (0.001, 0.199)
Matorras (1991)23
Morales (1986)26
Tuppurainen (1989)27
Benitz (1999)31 1 ! 3 *Allardice (1982)48 M-H OR
with continuity correction
0.19 (0.07, 0.53) 0.103 (0.023, 0.470) 0.092 (0.012, 0.346)
Morales (1986)26
Tuppurainen (1989)27
Matorras (1991)23
*Pylipow (1994)49
Allen (1993)32 1 ! 3 Boyer (1986)28 M-H OR without
continuity correction
0.03 (0.0013, 0.17) 0.025 (0.004, 0.187) 0.017 (0.001, 0.095)
*Boyer (1986)28
*Allardice (1982)48
*Morales (1987)50
Morales (1986)26
Matorras (1991)23
Tuppurainen (1989)27
Ohlsson (2014)9 1 ! 3 Boyer (1986) 28 M-H RR with continuity
correction
0.17 (0.04, 0.74) 0.097 (0.014, 0.696)† 0.062 (0.002, 0.368)‡
Matorras (1991)23
Tuppurainen (1989)27
*Non-randomised studies.
† M-H RR
‡ Bayesian FE RR35
NOTE: Reviews did not necessarily extract the same data from each study
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and perform separate analyses for each outcome of interest.
This has led to all previous analyses treating the outcomes as
unrelated, failing to use all the available evidence or taking
into account dependencies and overlaps in the data. One
approach would be to treat the 1 ! 2 and 1 ! 3 outcomes
as correlated in a MVNRE meta-analysis.5 This would take
account of the within- and between-study correlations, but
the analysis would be identical if the outcomes were two dif-
ferent ways of measuring depression, or if one outcome was
the risk of stroke, and the other the risk of bleeding. The
MPES models presented here, by contrast, are intended to
capture structural and clinical relationships, and provide a
range of outputs in the way of transition-specific risk ratios,
and model checking, that have a natural clinical
interpretation.
The multi-state models proposed in this paper are related
to a much wider set of models for aggregate event history
data using rate models and hazard ratios.56 These methods
include multiple end-state (or competing risk) models,57
models using the Kolmogorov forward equations for data on
fully or partially observed Markov processes58,59 and models
synthesising data on multiple-outcomes8 and over multiple
follow-up times.7 In the case of the EOGBS data, although
the lack of a time-element does not allow for event history
analysis, the conditional, sequence of outcomes can be used
to conduct a coherent analysis.
The most recent Cochrane review,9 which concludes
“there is a lack of evidence … to recommend IAP” takes all-
cause mortality as the primary outcome, rather than EOGBS,
and entirely excludes most of the evidence, which is on new-
born colonisation. Only one trial28 reports neonatal mortal-
ity, with 0/79 deaths in the IAP arm and 2/85 in controls
(one death was due to GBS, the other to other causes).
One naturally hesitates before making a treatment recom-
mendation based on such sparse data. However, to treat neo-
natal EOGBS mortality as if it is unrelated to EOGBS, or to
GBS colonisation of the newborn, is reductionism60 taken to
an illogical extreme. Deaths due to EOGBS can only occur
in infants with EOGBS, so prevention of EOGBS is a neces-
sary and sufficient condition to prevent EOGBS-related mor-
tality. Similarly, to the extent that EOGBS can only occur
following newborn colonisation, it would also be reasonable
to take newborn colonisation by GBS as a reasonable proxy
outcome.
Indeed, if we accept that the effect of IAP on EOGBS
mortality is the target parameter, our multi-state approach
readily provides an estimate. If we conservatively assume
that there is no effect of treatment on EOGBS mortality in
newborns with EOGBS, then the RR of IAP for neonatal
mortality due to EOGBS is 0.03 (0.002, 0.13), the same as
the effect on EOGBS. As there is evidence that IAP also
prevents other early onset disease61,62 the effect on all-cause
mortality can only be greater than this.
We have shown how a MPES framework can be used to
jointly synthesise all relevant evidence and to check that the
underlying assumptions are statistically supported by the evi-
dence available. The starting point for this type of model is
an assumption on the clinical relationship between out-
comes, which must be clinically plausible and validated by
experts.
Similar methods can be applied to trials on fertility treat-
ments where embryo fertilisation, implantation, clinical
pregnancy, ongoing pregnancy and birth must follow in
order, and the survival of the embryo/fetus at each stage is
conditional on survival at the previous stage. Many other
multiple outcome evidence structures exist, where a joint
synthesis respecting clinical and logical structure provides a
more robust basis for systematic review and decision mak-
ing,6-8,58 especially if formal methods such as cost-
effectiveness analysis are employed.63,64
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